Redwood Pharma specializes in developing ophthalmic medications in regions with particularly high medical demand. Dry eye disease (DED) presents significant opportunities as it affects around 344 million individuals globally, creating a market worth USD 3.1 billion. The market is projected to expand, primarily due to the absence of effective treatments. Our initial project, RP101, focuses on addressing chronic dry eyes in post-menopausal women. This achievement is made possible by our proprietary drug delivery platform, IntelliGel, which regulates the release of active ingredients and facilitates enhanced dosing of conventional medications.